治疗3400万高血压患者的经验:全球HEARTS倡议
全球仅约五分之一高血压患者血压得到控制。本文总结常见障碍与成功促进因素,分享多国合作经验。
要点
- 线性药物和剂量特异性治疗方案有效、节省成本,并允许非医师卫生工作者参与高血压治疗。
- 可靠获得可负担、质量有保证的药物往往是项目推广的关键瓶颈,需情境化策略改善药品供应。
- 有效数字系统、团队护理与任务转移、消除用户费用及多月份处方等策略有助于提高治疗 uptake、保留和控制率。
核心结论
- 若全球组织和国家卫生项目优先实施世界卫生组织HEARTS规划,实现50%社区血压控制是触手可及的。
研究设计与样本
- 本文描述性总结自2017年以来Resolve to Save Lives与多国政府及其他利益相关方合作支持基于HEARTS的高血压控制项目的经验。
主要发现
- 尽管治疗费用可低于每患者每年5美元,但可靠获得可负担、质量有保证的药物常是项目推广的关键瓶颈。
- 项目启动后药品需求呈指数增长,许多资源受限国家需要额外投资,且近期无可能的外部资金来源。
关键数值与推荐
- 线性药物和剂量特异性治疗方案有效、节省成本,并允许非医师卫生工作者参与高血压治疗。
- 实施国家制定的方案可提高采纳率;国家需通过倡导和指导来转变提供者行为及阻碍全面实施的政策障碍。
- 改善药品供应的策略因情境而异,包括基于发病率的预测和倡导增加资金并将方案药物纳入国家基本药物目录。
- 有效数字系统提供实时信息以改善患者管理和项目绩效,以用户为中心、离线优先的数字信息系统及关注关键指标(尤其是血压控制率)有助于稳步进展。
- 团队护理和任务转移面临政策和制度障碍,需要倡导有利政策、基于能力的培训、结构化指导和监督。
临床怎么用
- 采用线性药物和剂量特异性治疗方案,允许非医师卫生工作者参与治疗。
- 实施国家制定的方案,并通过倡导和指导转变提供者行为及政策障碍。
- 采用情境化策略改善药品供应,如基于发病率的预测和倡导增加资金、将方案药物纳入国家基本药物目录。
- 建立以用户为中心、离线优先的数字信息系统,关注血压控制率等关键指标。
- 采取消除用户费用(包括药品)、治疗分散化、为血压稳定控制患者提供多月份处方及整合入初级保健服务等策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hypertension is the leading cause of preventable death globally, yet only approximately 1 in 5 people with hypertension have their blood pressure (BP) controlled, despite availability of effective, generic medicines and the World Health Organization HEARTS technical package of effective, scalable hypertension control interventions. Since 2017, Resolve to Save Lives has collaborated with national governments and other stakeholders to support HEARTS-based hypertension control programs. By December 2024, approximately 34 million people were started on treatment at >220,000 primary care facilities across 38 countries. This paper describes common barriers to and facilitators of success and shares lessons learned from this ongoing multi-country collaboration. Linear drug- and dose-specific treatment protocols are effective, cost saving, and allow nonphysician health care workers to participate in hypertension treatment. Implementing country-developed protocols improves uptake; countries needed to use advocacy and mentoring to shift provider behaviors and policy barriers hindering full implementation. Although treatment can cost <U.S.$5 per patient per year, reliable access to affordable, quality-assured medicines is often a critical bottleneck to program scale-up. Strategies to improve drug supply are context specific and include morbidity-based forecasting and advocacy to increase funding and include protocol medicines in national essential medicines lists. Demand for medicines increases exponentially once programs start, and many resource-constrained countries require additional investments; no likely external funding sources are on the horizon. An effective digital system that provides real-time information to improve patient management and program performance is critical to scale HEARTS programs. User-centered, off-line-first digital information systems, and focus on critical metrics, particularly BP control rate, facilitate steady progress. Team-based care and task shifting face policy and institutional barriers requiring advocacy for enabling policies, competency-based training, structured mentoring, and supervision. Strategies that improve treatment uptake, retention in care, and control include eliminating user fees including for medicines, treatment decentralization, multimonth prescriptions for patients with stable controlled BP, and integration into primary care services. Achieving 50% community BP control is within reach if global organizations and national health programs prioritize implementing the World Health Organization HEARTS program.
引用
- Banigbe BF, Moran AE, Gupta R, et al. Lessons Learned From Treating 34 Million People With Hypertension: The Global HEARTS Initiative. J Am Coll Cardiol. 2025. PMID: 41338844. doi:10.1016/j.jacc.2025.09.324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。